Arovella Therapeutics Past Earnings Performance
Past criteria checks 0/6
Arovella Therapeutics's earnings have been declining at an average annual rate of -5.4%, while the Pharmaceuticals industry saw earnings growing at 35.4% annually. Revenues have been growing at an average rate of 15.8% per year.
Key information
-5.4%
Earnings growth rate
49.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 31.2% |
| Revenue growth rate | 15.8% |
| Return on equity | -77.9% |
| Net Margin | -448.0% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Arovella Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 2 | -9 | 2 | 7 |
| 31 Mar 24 | 2 | -9 | 3 | 6 |
| 31 Dec 23 | 2 | -10 | 3 | 6 |
| 30 Sep 23 | 2 | -10 | 3 | 5 |
| 30 Jun 23 | 1 | -10 | 2 | 4 |
| 31 Mar 23 | 2 | -9 | 2 | 4 |
| 31 Dec 22 | 2 | -9 | 2 | 4 |
| 30 Sep 22 | 1 | -9 | 2 | 3 |
| 30 Jun 22 | 0 | -9 | 2 | 3 |
| 31 Mar 22 | 0 | -8 | 2 | 2 |
| 31 Dec 21 | 1 | -7 | 2 | 1 |
| 30 Sep 21 | 1 | -6 | 2 | 1 |
| 30 Jun 21 | 1 | -5 | 1 | 1 |
| 31 Mar 21 | 1 | -5 | 1 | 0 |
| 31 Dec 20 | 1 | 2 | 1 | 0 |
| 30 Sep 20 | 1 | -1 | 1 | 0 |
| 30 Jun 20 | 1 | -4 | 1 | 0 |
| 31 Mar 20 | 1 | -12 | 2 | 0 |
| 31 Dec 19 | 1 | -15 | 1 | 0 |
| 30 Sep 19 | 1 | -11 | 1 | 0 |
| 30 Jun 19 | 1 | -8 | 1 | 0 |
| 31 Mar 19 | 1 | -6 | 1 | 0 |
| 31 Dec 18 | 1 | -5 | 2 | 0 |
| 30 Sep 18 | 1 | -5 | 2 | 0 |
| 30 Jun 18 | 0 | -6 | 2 | 0 |
| 31 Mar 18 | 5 | -4 | 2 | 0 |
| 31 Dec 17 | 1 | -3 | 2 | 0 |
| 30 Sep 17 | 1 | -2 | 2 | 0 |
| 30 Jun 17 | 1 | -1 | 1 | 0 |
| 31 Mar 17 | 4 | -1 | 2 | 0 |
| 31 Dec 16 | 3 | -1 | 2 | 0 |
| 30 Sep 16 | 5 | -2 | 2 | 0 |
| 30 Jun 16 | 6 | -2 | 3 | 0 |
| 31 Mar 16 | 6 | -3 | 2 | 0 |
| 31 Dec 15 | 6 | -3 | 2 | 0 |
| 30 Sep 15 | 6 | -3 | 2 | 0 |
| 30 Jun 15 | 6 | -3 | 3 | 0 |
| 31 Mar 15 | 6 | -4 | 3 | 0 |
| 31 Dec 14 | 6 | -4 | 3 | 0 |
| 30 Sep 14 | 7 | -3 | 3 | 0 |
| 30 Jun 14 | 9 | -2 | 2 | 0 |
| 31 Mar 14 | 8 | -2 | 2 | 0 |
| 31 Dec 13 | 8 | -1 | 2 | 0 |
Quality Earnings: ALA is currently unprofitable.
Growing Profit Margin: ALA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ALA is unprofitable, and losses have increased over the past 5 years at a rate of 5.4% per year.
Accelerating Growth: Unable to compare ALA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (46.5%).
Return on Equity
High ROE: ALA has a negative Return on Equity (-77.89%), as it is currently unprofitable.